Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

36.95 USD -0.20 (-0.54%)
Streaming Delayed Price Updated: 9:42 AM EST, Dec 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,317
Open 37.01
Bid (Size) 36.93 (1)
Ask (Size) 37.23 (2)
Prev. Close 37.15
Today's Range 36.66 - 37.19
52wk Range 37.05 - 98.39
Shares Outstanding 58,908,485
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their... 
From Business Wire News Releases
Sage Therapeutics to Host Sage FutureCast Webcast
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,... 
From Business Wire News Releases

Performance

YTD
-56.94%
-56.94%
1 Month
-12.79%
-12.79%
3 Month
-21.10%
-21.10%
6 Month
-45.73%
-45.73%
1 Year
-49.13%
-49.13%

More News

Read More
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From Business Wire News Releases
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
From Business Wire News Releases
Artificial Intelligence Could Be About To Replace Your Doctor
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
Tags major depressive disorder SAGE Benzinga
From Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Tags MEIP SABS News
From Benzinga
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Business Wire News Releases
12 Health Care Stocks Moving In Friday's After-Market Session
Tags Market News Movers SRGA
From Benzinga
What 8 Analyst Ratings Have To Say About Sage Therapeutics
Tags Analyst Ratings Market News BZI/AAR
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.